US3896233A - Pharmaceutical compositions and methods of inhibiting gastric acid secretion - Google Patents

Pharmaceutical compositions and methods of inhibiting gastric acid secretion Download PDF

Info

Publication number
US3896233A
US3896233A US507093A US50709374A US3896233A US 3896233 A US3896233 A US 3896233A US 507093 A US507093 A US 507093A US 50709374 A US50709374 A US 50709374A US 3896233 A US3896233 A US 3896233A
Authority
US
United States
Prior art keywords
pyridyl
morpholino
thioacetamide
morpholinomethyl
gastric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US507093A
Inventor
L Martin Brenner
Bernard Loev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US00266024A external-priority patent/US3853865A/en
Application filed by SmithKline Corp filed Critical SmithKline Corp
Priority to US507093A priority Critical patent/US3896233A/en
Application granted granted Critical
Publication of US3896233A publication Critical patent/US3896233A/en
Assigned to SMITHKLINE BECKMAN CORPORATION reassignment SMITHKLINE BECKMAN CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). EFFECTIVE DATE: 03/04/82 Assignors: SMITHKLINE CORPORATION
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to new N-aminomethyl-Z- amino- (and Z-aminomethyl)-2-heterocyclicthioacetamides having pharmacological activity.
  • these compounds inhibit gastric acid secretion.
  • n O or 1;
  • R is 2-pyridyl, 2pyrimidyl, 4-pyrimidyl, 2-pyrazinyl, Z-pyrrolyl, 2-quinolyl, 2-thiazolyl or 4-thiazolyl;
  • R and R are di-lower alkylamino, N-lower alkyl-N- phenylamino, piperidino, pyrrolidino, morpholino or Nlower alkylpiperazino.
  • This invention also includes pharmaceutically acceptable acid addition salts of the compounds of Formula I.
  • the pharmacologically active compounds of this invention have the basic structure of Formula I. However, it is apparent to one skilled in the art that well known nuclear substituents such as lower alkyl, lower alkoxy or halogen may be incorporated on the heterocyclic rings of R and the phenyl rings. These compounds are used as are the parent compounds.
  • Preferred compounds of this invention are represented by Formula I in which m is O or 1 and R is dimethylamino, diethylamino, piperidino or pyrrolidino or m is l and R is morpholino, and R is di-lower alkylamino, piperidino, pyrrolidino or morpholino.
  • R is pyridyl
  • Advantageous compounds of this invention are represented by Formula I in which R is Z-pyridyl, m is O or 1 and R is dimethylamino or m is l and R is morpholino, and R is diethylamino, pyrrolidino or morpholino.
  • a particularly advantageous compound of this invention is 3-morpholino-N-morpholinomethyl-2-(2- pyridyl)-thiopropanamide.
  • the compounds of this invention produce inhibition of gastric acid secretion. This activity is demonstrated by administration to pylorus ligated rats at doses of about to about 50 mg./kg. orally. Also, this activity is demonstrated by administration to chronic gastric fistula rats (Brodie et al., Amer. J. Physiol, 202:812-8l4, 1962) at doses of about 30 to about 50 rug/kg. orally. In these procedures, compounds which produce an increase in the gastric pH or a decrease in the volume of gastric juice or both are considered active.
  • a 2-amino(or 2- aminomethyl)'2-heterocyclic-thioacetamide is reacted with formaldehyde and an amine.
  • the reaction is preferably carried out in an organic solvent, such as a lower alkanol, for example methanol.
  • the reaction is carried out at about -40C. to about C.
  • the 2-amino(or 2-aminomethyl)-2-heterocyclicthioacetamide starting materials are prepared by the following procedures.
  • R and R are as defined above and R is an alkali metal.
  • a heterocycliccarboxoaldehyde, an amine and an alkali metal cyanide are reacted, preferably in the presence of acid, to give a 2-amino-2-heterocyclic-acetonitrile which is converted to a 2-amino-2-heterocyclic-thioacetamide by reacting with hydrogen sulfide in the presence of a base such as an amine or by reacting with ammonium polysulfide.
  • the 2-aminomethyl-2-heterocyclic-thioacetamide starting materials are prepared by reacting a 2-heterocyclic-thioacetamide, 2-heterocyclicacetamide, or 2-heterocyclic-acetonitrile with an equimolar amount of formaldehyde and an equimolar amount of an amine to give the corresponding 2- aminomethyl compounds and where the intermediate is a 2-aminomethyl-2-heterocyclic-acetamide, reacting with phosphorus pentasulfide to give the corresponding thioacetamide and where the intermediate is 2- aminomethyl-2-heterocyclic-acetonitrile, reacting with hydrogen sulfide in the presence of a base such as an amine or by reacting with ammonium polysulfide to give the corresponding thioacetamide.
  • the pharmaceutically acceptable, acid addition salts of the compounds of Formula I are formed with organic and inorganic acids by methods known to the art.
  • the base is reacted with an organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.
  • aqueous miscible solvent such as acetone or ethanol
  • aqueous immiscible solvent such as ethyl ether or chloroform
  • Exemplary of the salts which are included in this invention are maleate, fumarate, succinate, oxalate, benzoate, methanesulfonate, ethanedisulfonate, benzenesulfonate, acetate, propionate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, sulfamate, phosphate and nitrate salts.
  • the compounds of this invention are administered internally either parenterally, rectally or, preferably, orally in an amount to produce the desired biological activity.
  • the compounds are administered in conventional dosage forms prepared by combining an appropriate dose of the compound with standard pharmaceutical carriers.
  • the pharmaceutical carrier may be for example a solid or a liquid.
  • solid carries are lactose, magnesium stearate, terra alba, sucrose, talc, stearic acid, gelatin, agar, pectin, acacia or cocoa butter.
  • the amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 gm.
  • liquid carriers are syrup, peanut oil, olive oil, sesame oil, propylene glycol, polyethylene glycol (mol. wt. 200-400) and water.
  • the carrier or diluent may include a time delay material well known to the art such as, for example, glyceryl monostearate or glyceryl distearate alone or with a wax.
  • compositions may take the form of tablets, capsules, powders, suppositories, troches, lozenges, syrups, emulsions, sterile injectable liquids or liquid suspensions or solutions.
  • compositions are prepared by conventional techniques involving procedures such as mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the methods of inhibiting gastric acid secretion in accordance with this invention comprise administering internally to an animal an effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.
  • the active ingredients will preferably be administered in dosage unit form as described above.
  • the compounds of this invention will be administered in a daily dosage regimen of from about 10 mg. to about 2 g., preferably from about 25 mg. to about 1 g.
  • equal doses will be administered one to four times per day.
  • Dosage units will contain from about 10 mg. to about 500 mg., preferably from about 25 mg. to about 250 mg., of the active ingredient.
  • lower alkyl and lower alkoxy where used herein denote groups having l4 carbon atoms and halogen denotes chloro, bromo or fluoro.
  • the yellow eluant is collected, the solvent removed and the residual liquid applied to an ethyl acetate slurried Florisil (magnesia-silica gel) column. Again the yellow eluant is concentrated and the residual viscous liquid is triturated with ethyl acetate and left at 20C. for 18 hours. The resulting precipitate is filtered and washed with cold ethyl acetate to give 3-morpholino-N- morpholinomethyl-2-(Z-pyridyl)thiopropanarnide, m.p. l09l l 1C.
  • 2-Dimethylamino-2- 2-pyridyl)acetonitrile (l 1.4 g., 0.07 mole) is dissolved in 200 ml. of dry pyridine containing 5 ml. of anhydrous triethylamine. Hydrogen sulfide is bubbled into the stirred solution for 7 hours and the solution is then stirred for 17 hours. This procedure is repeated for 5 days. Then the mixture is stirred for an additional 48 hours. The solvent is then removed under reduced pressure and the residue is recrystallized from ethanol to give Z-dimethylamino-Z-(Z- pyridyl)thioacetamide, m.p. 130-133C. (dec.).
  • 2-Morpholino-2-(2-pyridyl)thioacetamide (1.0 g., 0.0042 mole) is dissolved with heating in ml. of methanol. To the warm solution is added 1.0 g. (0.012 mole) of morpholine and 1.84 g. (0.022 mole) of 37% aqueous formaldehyde solution. The resulting solution is refluxed 3 hours and then stirred for 17 hours. The solvent is evaporated and the residue is recrystallized from methanol/ether to give 2-morpho1ino-N- morpholinomethyl-2-(2-pyridyl)thioacetamide, m.p. 144l47C. (dec.).
  • EXAMPLE 6 To 27.0 g of 2-pyrimidinecarboxaldehyde and 1 1.3 g. of dimethylamine (neutralized with hydrochloric acid) is added, with stirring and cooling, 17.9 g. of potassium cyanide in a small amount of water. The mixture is allowed to stand overnight and ether is added. Concentrating and distilling the residue gives 2- dimethylamino-2-(2-pyrimidyl)-acetonitri1e.
  • the product is 2- dipropylamino N-morpholinomethyl-2-(2- 5 pyridyl)thioacetamide.
  • the product is Z-dibutylamino-N-morpholinomethyl-2-(2- pyridyl)-thioacetamide.
  • EXAMPLE 12 A solution of 3.0 g. (0.019 mole) of 2-(2-pyridyl)- thioacetamide in 40 ml. of anhydrous methanol is treated at 40C. with 1.7 g. (0.019 mole) of morpholine in 5 ml. of methanol and 1.6 ml. of 37% formalin solution. The resulting mixture is kept at -C. for 36 hours.
  • N-dimethylaminomethyl-3-morpholino-2-(2- pyridyl)-thiopropanamide N-diethylaminomethyl-3-morpholino-2-(2-pyridyl)- thiopropanamide 8 3-morpholino-N-piperidinomethyl-2-( 2-pyridyl thiopropanamide N-( 4-methylpiperazinomethyl)-3-morpholino-2-( 2- pyridyl )-thiopropanamide.
  • EXAMPLE 16 Using N-methylaniline in place of dimethylamine in the procedure of Example 2, the product is 2-(N- methyl-N-phenylamino)-N-morpholinomethyl-2-(2- pyridyl)thioacetamide.
  • EXAMPLE 18 Ingredients Amounts 3-Morpholino-N-morpholinomethyl- 2-(Z-pyridyl)thiopropanamide 150 mg. Lactose 100 mg. Magnesium stearate 5 mg.
  • the ingredients are mixed and filled into a hard gelatin capsule.
  • sucrose, calcium sulfate dihydrate and 2- dimethylamino-N-morpholinomethyl-2-(2- pyridyl)thioacetamide are thoroughly mixed and granulated with gelatin solution.
  • the set granules are screened, dried and then mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
  • compositions prepared as in Examples 18 and 19 are administered orally to a subject having excessive gastric acid secretion within the dose ranges given hereabove.
  • a pharmaceutical composition having gastric acid secretion inhibitory activity, in dosage unit form, comprising a pharmaceutical carrier and an effective gastric acid secretion inhibiting amount of a thioamide compound of the formula:
  • n O or 1;
  • R is Z-pyridyl
  • R and R are di-lower alkylamino, N-lower alkyl-N- phenylamino, piperidino, pyrrolidino or morpholino or a pharmaceutically acceptable acid addition salt thereof.
  • composition of claim 1 in which m is 0 or 1 and R is dimethylamino, diethylamino, piperidino or pyrrolidino or m is l and R is morpholino, And R is di-lower alkylamino, piperidino, pyrrolidino or'morpholino.

Abstract

Pharmaceutical compositions and methods of inhibiting gastric acid secretion by administering N-aminomethyl-2-amino(and 2aminomethyl)-2-heterocyclicthioacetamides.

Description

United States Patent [191 Brenner et al.
[ PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING GASTRIC ACID SECRETION [75] Inventors: L. Martin Brenner, Havertown;
Bernard Loev, Broomall, both of Pa.
[73] Assignee: SmithKline Corporation,
Philadelphia, Pa.
[22] Filed: Sept. 18, 1974 21 Appl. No.: 507,093
Related U.S. Application Data [63] Continuation-in-part of Ser. No. 266,024, June 26,
1972, Pat. N0. 3,853,865.
[52] U.S. Cl. 424/248; 424/250; 424/251; 424/258; 424/263; 424/267;
[51] Int. Cl A6lk 27/00 July 22, 1975 Primary ExaminerFrederick E. Waddell Attorney, Agent, or Firm-Joan S. Keps; Richard D. Foggio; William H. Edgerton 57] ABSTRACT Pharmaceutical compositions and methods of inhibiting gastric acid secretion by administering N-aminomethyl-2-amino(and 2-aminomethyl)-2- heterocyclicthioacetamides.
8 Claims, No Drawings 1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING GASTRIC ACID SECRETION This application is a continuation-in-part of Ser. No. 266,024, filed June 26, 1972, now US. Pat. No. 3,853,865.
This invention relates to new N-aminomethyl-Z- amino- (and Z-aminomethyl)-2-heterocyclicthioacetamides having pharmacological activity. In particular, these compounds inhibit gastric acid secretion.
The compounds of this invention are represented by the following formula:
FORMULA I in which:
m is O or 1;
R is 2-pyridyl, 2pyrimidyl, 4-pyrimidyl, 2-pyrazinyl, Z-pyrrolyl, 2-quinolyl, 2-thiazolyl or 4-thiazolyl; and
R and R are di-lower alkylamino, N-lower alkyl-N- phenylamino, piperidino, pyrrolidino, morpholino or Nlower alkylpiperazino.
This invention also includes pharmaceutically acceptable acid addition salts of the compounds of Formula I.
The pharmacologically active compounds of this invention have the basic structure of Formula I. However, it is apparent to one skilled in the art that well known nuclear substituents such as lower alkyl, lower alkoxy or halogen may be incorporated on the heterocyclic rings of R and the phenyl rings. These compounds are used as are the parent compounds.
Preferred compounds of this invention are represented by Formula I in which m is O or 1 and R is dimethylamino, diethylamino, piperidino or pyrrolidino or m is l and R is morpholino, and R is di-lower alkylamino, piperidino, pyrrolidino or morpholino.
Most preferably, in the compounds of Formula I, R is pyridyl.
Advantageous compounds of this invention are represented by Formula I in which R is Z-pyridyl, m is O or 1 and R is dimethylamino or m is l and R is morpholino, and R is diethylamino, pyrrolidino or morpholino.
A particularly advantageous compound of this invention is 3-morpholino-N-morpholinomethyl-2-(2- pyridyl)-thiopropanamide.
The compounds of this invention produce inhibition of gastric acid secretion. This activity is demonstrated by administration to pylorus ligated rats at doses of about to about 50 mg./kg. orally. Also, this activity is demonstrated by administration to chronic gastric fistula rats (Brodie et al., Amer. J. Physiol, 202:812-8l4, 1962) at doses of about 30 to about 50 rug/kg. orally. In these procedures, compounds which produce an increase in the gastric pH or a decrease in the volume of gastric juice or both are considered active.
s v s The terms m, R R and R are as defined above. II.
The terms m, R R and R are as defined above and R and R are the same.
According to procedure I, a 2-amino(or 2- aminomethyl)'2-heterocyclic-thioacetamide is reacted with formaldehyde and an amine. The reaction is preferably carried out in an organic solvent, such as a lower alkanol, for example methanol. The reaction is carried out at about -40C. to about C.
According to procedure II, a heterocyclic thioacetamide is reacted with two molar equivalents of formaldehyde and two molar equivalents of an amine to give compounds of this invention in which m is l and R and R are the same.
The 2-amino(or 2-aminomethyl)-2-heterocyclicthioacetamide starting materials are prepared by the following procedures.
The terms R and R are as defined above and R is an alkali metal.
According to the above procedure, a heterocycliccarboxoaldehyde, an amine and an alkali metal cyanide are reacted, preferably in the presence of acid, to give a 2-amino-2-heterocyclic-acetonitrile which is converted to a 2-amino-2-heterocyclic-thioacetamide by reacting with hydrogen sulfide in the presence of a base such as an amine or by reacting with ammonium polysulfide.
The 2-aminomethyl-2-heterocyclic-thioacetamide starting materials are prepared by reacting a 2-heterocyclic-thioacetamide, 2-heterocyclicacetamide, or 2-heterocyclic-acetonitrile with an equimolar amount of formaldehyde and an equimolar amount of an amine to give the corresponding 2- aminomethyl compounds and where the intermediate is a 2-aminomethyl-2-heterocyclic-acetamide, reacting with phosphorus pentasulfide to give the corresponding thioacetamide and where the intermediate is 2- aminomethyl-2-heterocyclic-acetonitrile, reacting with hydrogen sulfide in the presence of a base such as an amine or by reacting with ammonium polysulfide to give the corresponding thioacetamide.
The pharmaceutically acceptable, acid addition salts of the compounds of Formula I are formed with organic and inorganic acids by methods known to the art. For example, the base is reacted with an organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Exemplary of the salts which are included in this invention are maleate, fumarate, succinate, oxalate, benzoate, methanesulfonate, ethanedisulfonate, benzenesulfonate, acetate, propionate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, sulfamate, phosphate and nitrate salts.
The compounds of this invention are administered internally either parenterally, rectally or, preferably, orally in an amount to produce the desired biological activity.
Preferably, the compounds are administered in conventional dosage forms prepared by combining an appropriate dose of the compound with standard pharmaceutical carriers.
The pharmaceutical carrier may be for example a solid or a liquid. Exemplary of solid carries are lactose, magnesium stearate, terra alba, sucrose, talc, stearic acid, gelatin, agar, pectin, acacia or cocoa butter. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 gm. Exemplary of liquid carriers are syrup, peanut oil, olive oil, sesame oil, propylene glycol, polyethylene glycol (mol. wt. 200-400) and water. The carrier or diluent may include a time delay material well known to the art such as, for example, glyceryl monostearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed, for example the preparation may take the form of tablets, capsules, powders, suppositories, troches, lozenges, syrups, emulsions, sterile injectable liquids or liquid suspensions or solutions.
The pharmaceutical compositions are prepared by conventional techniques involving procedures such as mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
The methods of inhibiting gastric acid secretion in accordance with this invention comprise administering internally to an animal an effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof. The active ingredients will preferably be administered in dosage unit form as described above.
The compounds of this invention will be administered in a daily dosage regimen of from about 10 mg. to about 2 g., preferably from about 25 mg. to about 1 g. Advantageously, equal doses will be administered one to four times per day. Dosage units will contain from about 10 mg. to about 500 mg., preferably from about 25 mg. to about 250 mg., of the active ingredient.
When administration is carried out as described above, gastric acid secretion is inhibited.
One skilled in the art will recognize that in determining the amounts of the active ingredients in the claimed compositions and used in the claimed methods, the activity of the chemical ingredient as well as the size of the host animal must be considered.
The terms lower alkyl" and lower alkoxy where used herein denote groups having l4 carbon atoms and halogen denotes chloro, bromo or fluoro.
The following examples are not limiting but are illustrative of the compounds of this invention and pro-. cesses for their preparation.
EXAMPLE 1 2-(2-Pyridyl)thioacetamide (0.7 g., 0.0046 mole) is dissolved in 10 ml. of methanol. The solution is cooled to about 40C. and 1.0 g. (0.012 mole) of morpholine and 0.9 g. (0.012 mole) of 37% aqueous formaldehyde solution are added simultaneously. The mixture is allowed to stand at 20C. for 48 hours, then the solvent is removed under reduced pressure (no heat is applied). The viscous liquid is chromatographed on an acetone slurried Florisil (magnesia-silica gel) column. The yellow eluant is collected, the solvent removed and the residual liquid applied to an ethyl acetate slurried Florisil (magnesia-silica gel) column. Again the yellow eluant is concentrated and the residual viscous liquid is triturated with ethyl acetate and left at 20C. for 18 hours. The resulting precipitate is filtered and washed with cold ethyl acetate to give 3-morpholino-N- morpholinomethyl-2-(Z-pyridyl)thiopropanarnide, m.p. l09l l 1C.
EXAMPLE 2 To cold 2-pyridinecarboxyaldehyde (21.4 g., 0.2 mole) is added dimethylamine (22.5 g. of a 40% aqueous solution, 0.2 mole) and the solution is neutralized with concentrated hydrochloric acid. To the stirred neutralized solution is added 14.4 g. (0.22 mole) of potassium cyanide. The mixture is stirred overnight, then diluted with water, transferred to a separatory funnel and repeatedly extracted with chloroform. The combined chloroform extracts are washed three times with water, once with brine and dried over magnesium sulfate. The mixture is filtered, the solvent is removed under reduced pressure and methanol is added to the residue. The mixture is allowed to stand at -20C. for 18 hours, then filtered. The filtrate is concentrated and distilled in vacuo to give 2-dimethylamino-2-(2- pyridyl)-acetonitrile.
2-Dimethylamino-2- 2-pyridyl)acetonitrile (l 1.4 g., 0.07 mole) is dissolved in 200 ml. of dry pyridine containing 5 ml. of anhydrous triethylamine. Hydrogen sulfide is bubbled into the stirred solution for 7 hours and the solution is then stirred for 17 hours. This procedure is repeated for 5 days. Then the mixture is stirred for an additional 48 hours. The solvent is then removed under reduced pressure and the residue is recrystallized from ethanol to give Z-dimethylamino-Z-(Z- pyridyl)thioacetamide, m.p. 130-133C. (dec.).
To a solution of 1.8 g. (0.0091 mole) of 2-dimethy1' amino-2-(2-pyridyl)thioacetamide in ml. of methanol is added 0.9 g. (0.010 mole) of morpholine in 2 ml. of methanol and 0.9 g. (0.011 mole) of 37% aqueous formaldehyde solution in 2 ml. of methanol. The resulting solution is stirred at room temperature for 18 hours. The solvent is removed under reduced pressure and ether is added to the residue. The mixture is cooled at 20C. for four hours and then filtered. The solvent is evaporated from the filtrate to give Z-dimethylamino- N-morpholinomethyl-2-(2-pyridyl)-thioacetamide.
EXAMPLE 3 Hydrogen sulfide is bubbled into a stirred solution of 10.0 g. (0.048 mole) of 2-morpholino-2-(2-pyridyl) acetonitrile, dissolved in 200 ml. of dry pyridine containing 5 ml. of anhydrous triethylamine, for 7 hours and then the mixture is stirred for 17 hours. Hydrogen sulfide is again bubbled into the stirred mixture and the mixture is again stirred for 17 hours. Then the solvent is removed under reduced pressure and the residue is recrystallized from ethanol to give 2-morpholino-2-(2 pyridyl)thioacetamide, m.p. l72l75C. (dec.).
2-Morpholino-2-(2-pyridyl)thioacetamide (1.0 g., 0.0042 mole) is dissolved with heating in ml. of methanol. To the warm solution is added 1.0 g. (0.012 mole) of morpholine and 1.84 g. (0.022 mole) of 37% aqueous formaldehyde solution. The resulting solution is refluxed 3 hours and then stirred for 17 hours. The solvent is evaporated and the residue is recrystallized from methanol/ether to give 2-morpho1ino-N- morpholinomethyl-2-(2-pyridyl)thioacetamide, m.p. 144l47C. (dec.).
EXAMPLE 4 EXAMPLE 5 By the procedure of Example 1, using in place of 2-(2-pyridyl)thioacetamide, the following thioacetamides:
2-(2-pyrazinyl)thioacetamide 2-(2-pyrrolyl)thioacetamide 2-( 2-quinolyl )thioacetamide 2-(6-methyl-2-pyridyl)thioacetamide 2-(4-methoxy-2-pyridyl)thioacetamide 2-(4,6-dimethyl-2-pyrimidyl)thioacetamide products are, respectively:
3-morpholino-N-morpholinomethyl-2-(2-pyrazinyl)- thiopropanamide the 6 3-morpholino-N-morpholinomethyl-2-( 2-pyrrolyl)- thiopropanamide 3-morpholino N-morpholinomethyl-2-( 2-quinolyl)- thiopropanamide Y 3-morphalino-N-morpholinomethyl-2-( 6-methyl-2- pyridyl)-thiopropanamide 3-morpholino-N-morpholinomethyl-2-(4-methoxy-2- pyridyl)-thiopropanamide 3-morpholino-N-morpholinomethyl-2-( 4,6-dimethyl- Z-pyrimidyl)thiopropanamide.
EXAMPLE 6 EXAMPLE 7 To 27.0 g of 2-pyrimidinecarboxaldehyde and 1 1.3 g. of dimethylamine (neutralized with hydrochloric acid) is added, with stirring and cooling, 17.9 g. of potassium cyanide in a small amount of water. The mixture is allowed to stand overnight and ether is added. Concentrating and distilling the residue gives 2- dimethylamino-2-(2-pyrimidyl)-acetonitri1e.
Using 2-dimethy1amino-2-(2-pyrimidyl)acetonitrile in place of 2-dimethylamino-2-(2-pyridy1)acetonitrile in the procedure of Example 2 gives Z-dimethylamino- N-morpholinomethyl-2-(2-pyrimidyl)thioacetamide.
EXAMPLE 8 by the procedure of Example 2, using the following carboxaldehydes in place of 2-pyridinecarboxaldehyde:
4-pyrimidinecarboxaldehyde 2-pyrazinecarboxaldehyde 2-pyrrolecarboxaldehyde 2-thiazolecarboxa1dehyde 4-thiazolecarboxaldehyde the products are, respectively:
Z-dimethylamino-N-morpholinomethyl-2-(4- pyrimidyl)-thioacetamide 2-dimethylamino-N-morpholinomethyl-2-(2- pyrazinyl)-thioacetamide Z-dimethylamino-N-morpholinomethyl-2-(2-pyrrolyl)-thioacetamide 2-dimethylamino-N-morpholinomethyl-2-( 2- thiazolyl)-thioacetamide 2-dimethylamino-N-m0rpholinomethyl-2-(4- thiazolyl)-thioacetamide.
EXAMPLE 9 By the procedure of Example 2, using diethylamine in place of dimethylamine, the product diethylamino-N-morpholinomethyl-2-( 2- pyridyl)thioacetamide.
Similarly, using dipropylamine, the product is 2- dipropylamino N-morpholinomethyl-2-(2- 5 pyridyl)thioacetamide.
By the same procedure, using dibutylamine, the product is Z-dibutylamino-N-morpholinomethyl-2-(2- pyridyl)-thioacetamide.
EXAMPLE By the procedure of Example 1, using in place of morpholine the following l-lower alkylpiperazines:
l-ethylpiperazine l-propylpiperazine l-butylpiperazine the products are, respectively:
3-( 4-ethylpiperazino )-N-( 4-ethylpiperazinomethyl 2-(Z-pyridyl)thiopropanamide 3-(4-propylpiperazino)-N-(4- propylpiperazinomethyl)-2-(2-pyridyl)thiopropanamide 3-(4-butylpiperazino)-N-(4-butylpiperazinomethyl)- 2-(2-pyridyl)thiopropanamide.
EXAMPLE 1 1 by the procedure of Example 2, using the following l-lower alkylpiperazines in place of dimethylamine:
l-methylpiperazine l-ethylpiperazine l-propylpiperazine l-butylpiperazine the products are, respectively: 2-(4-methylpiperazino)-N-morpholinomethyl-2(2- pyridyl)-thioacetamide 2-(4-ethylpiperazino)-N-morpholinomethyl-2-(2- pyridyl)-thioacetamide N-morpholinomethyl-2-(4-propylpiperazino)-2-(2- pyridyl)thioacetamide 2-(4-butylpiperazino)-N-morpholin0methyl-2-(2- pyridyl)-thioacetamide.
EXAMPLE 12 A solution of 3.0 g. (0.019 mole) of 2-(2-pyridyl)- thioacetamide in 40 ml. of anhydrous methanol is treated at 40C. with 1.7 g. (0.019 mole) of morpholine in 5 ml. of methanol and 1.6 ml. of 37% formalin solution. The resulting mixture is kept at -C. for 36 hours.
The solvents are evaporated in vacuo at 25C. and the residue is triturated three times with ether in the cold. The ether is decanted and the residue is recrystallized from acetone/hexane to give 3-morpholino-2-(2- pyridyl)thiopropanamide.
The above prepared 3-morpholino-2-(2-pyridyl)- thiopropanamide is reacted with pyrrolidine and formaldehyde in methanol by the procedure of Example 2 to give 3-morph01ino-N-pyrrolidinomethyl-2-(2- pyridyl)thiopropanamide.
By the same procedure, using the following compounds in place of pyrrolidine:
dimethylamine diethylamine piperidine l-methylpiperazine the products are, respectively:
N-dimethylaminomethyl-3-morpholino-2-(2- pyridyl)-thiopropanamide N-diethylaminomethyl-3-morpholino-2-(2-pyridyl)- thiopropanamide 8 3-morpholino-N-piperidinomethyl-2-( 2-pyridyl thiopropanamide N-( 4-methylpiperazinomethyl)-3-morpholino-2-( 2- pyridyl )-thiopropanamide.
EXAMPLE 13 One gram of 3-morpholino-N-morpholinomethyl-2- (2-pyridyl)thiopropanamide in ethanol is treated with ethereal hydrogen chloride and the solvents are removed under reduced pressure to give 3-morpholino- N-morpholinomethyl-2-(2-pyridyl)thiopropanamide trihydrochloride.
similarly, using ethereal hydrogen bromide, the hydrobromide salt is prepared.
EXAMPLE l4 2-Dimethylamino-N-morpholinomethyl-2-(2- pyridyl)-thioacetamide in ethanol is treated with an equimolar amount of oxalic acid in ethanol to give, after removing the solvent under reduced pressure, 2- dimethylamino-N-morpholin0methyl-2-(2- pyridyl)thioacetamide oxalate.
Similarly, using maleic acid, Z-dimethylamino-N- morpholinomethyl-2-(2-pyridyl)thioacetamide maleate is prepared.
In the same manner, using citric acid, 2-
dimethylamino-N-morpholinomethyl-2-(2- pyridyl)thioacetamide citrate is prepared.
EXAMPLE [5 EXAMPLE 16 Using N-methylaniline in place of dimethylamine in the procedure of Example 2, the product is 2-(N- methyl-N-phenylamino)-N-morpholinomethyl-2-(2- pyridyl)thioacetamide.
Similarly, using the approriate N-lower alkyl-anilines, the corresponding N-ethyl, N-propyl and N-butyl compounds are prepared.
EXAMPLE 17 By the procedure of Example 2, using in place of morpholine, the following amines:
pyrrolidine piperidine l -methylpiperazine diethylamine the products are, respectively:
2-dimethylamino-N-pyrrolidinomethyl-2-(2- pyridyl)-thioacetamide 2-dimethylamino-N-piperidinomethyl-2-(2-pyridyl)- thioacetamide Z-dimethylamino-N-(4 methylpiperazinomethyl)-2- (2-pyridyl )thioacetamide 9 2-dimethylamino-N-diethylaminomethyl-2-( 2- pyridyl)-thioacetamide.
EXAMPLE 18 Ingredients Amounts 3-Morpholino-N-morpholinomethyl- 2-(Z-pyridyl)thiopropanamide 150 mg. Lactose 100 mg. Magnesium stearate 5 mg.
The ingredients are mixed and filled into a hard gelatin capsule.
The sucrose, calcium sulfate dihydrate and 2- dimethylamino-N-morpholinomethyl-2-(2- pyridyl)thioacetamide are thoroughly mixed and granulated with gelatin solution. The set granules are screened, dried and then mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
The compositions prepared as in Examples 18 and 19 are administered orally to a subject having excessive gastric acid secretion within the dose ranges given hereabove.
What is claimed is:
1. A pharmaceutical composition having gastric acid secretion inhibitory activity, in dosage unit form, comprising a pharmaceutical carrier and an effective gastric acid secretion inhibiting amount of a thioamide compound of the formula:
in which:
m is O or 1;
R is Z-pyridyl; and
R and R are di-lower alkylamino, N-lower alkyl-N- phenylamino, piperidino, pyrrolidino or morpholino or a pharmaceutically acceptable acid addition salt thereof.
2. The pharmaceutical composition of claim 1 in which m is 0 or 1 and R is dimethylamino, diethylamino, piperidino or pyrrolidino or m is l and R is morpholino, And R is di-lower alkylamino, piperidino, pyrrolidino or'morpholino.
3. The pharmaceutical composition of claim 1 in which m is 0 or 1 and R is dimethylamino or m is 1 And R is morpholino, and R is diethylamino, pyrrolidino or morpholino.
4. The pharmaceutical composition of claim 1 in which the thioamide compound is 3-morph0lino-N- morpholinomethyl-2-(Z-pyridyl)thiopropanamide.
5. The pharmaceutical composition of claim 1 in which the thioamide is present in an amount of from about 10 mg. to about 500 mg.
6. A method of inhibiting gastric acid secretion in a subject having excessive gastric acid secretion which comprises administering internally to said subject an effective amount of a thioamide compound of the formula:
about 10 mg. to about 2 g.

Claims (8)

1. A PHARMACEUTICAL COMPOSITION HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY, IN DOSAGE UNIT FORM, COMPRISING A PHARMACEUTICAL CARRIER AND AN EFFECTIVE GASTRIC ACID SECRETION INHIBITING AMOUNT OF A THIOAMIDE COMPOUND OF THE FORMULA:
2. The pharmaceutical composition of claim 1 in which m is 0 or 1 and R2 is dimethylamino, diethylamino, piperidino or pyrrolidino or m is 1 and R2 is morpholino, And R3 is di-lower alkylamino, piperidino, pyrrolidino or morpholino.
3. The pharmaceutical composition of claim 1 in which m is 0 or 1 and R2 is dimethylamino or m is 1 And R2 is morpholino, and R3 is diethylamino, pyrrolidino or morpholino.
4. The pharmaceutical composition of claim 1 in which the thioamide compound is 3-morpholino-N-morpholinomethyl-2-(2-pyridyl)thiopropanamide.
5. The pharmaceutical composition of claim 1 in which the thioamide is present in an amount of from about 10 mg. to about 500 mg.
6. A method of inhibiting gastric acid secretion in a subject having excessive gastric acid secretion which comprises admInistering internally to said subject an effective amount of a thioamide compound of the formula:
7. The method of claim 6 in which the thioamide compound is 3-morpholino-N-morpholinomethyl-2-(2-pyridyl)-thiopropanamide.
8. The method of claim 6 in which the thioamide compound is administered in a daily dosage of from about 10 mg. to about 2 g.
US507093A 1972-06-26 1974-09-18 Pharmaceutical compositions and methods of inhibiting gastric acid secretion Expired - Lifetime US3896233A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US507093A US3896233A (en) 1972-06-26 1974-09-18 Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00266024A US3853865A (en) 1972-06-26 1972-06-26 N-aminomethyl-2-amino(and 2-amino-methyl)-2-heterocyclic-thioacetamides
US507093A US3896233A (en) 1972-06-26 1974-09-18 Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Publications (1)

Publication Number Publication Date
US3896233A true US3896233A (en) 1975-07-22

Family

ID=26951577

Family Applications (1)

Application Number Title Priority Date Filing Date
US507093A Expired - Lifetime US3896233A (en) 1972-06-26 1974-09-18 Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Country Status (1)

Country Link
US (1) US3896233A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203988A (en) * 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
US4241072A (en) * 1979-01-18 1980-12-23 Merck & Co., Inc. Substituted ureas and processes for their preparation
US4293703A (en) * 1979-01-18 1981-10-06 Merck & Co., Inc. Imidazole or imidazoline substituted ureas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842173A (en) * 1972-03-21 1974-10-15 Smithkline Corp Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842173A (en) * 1972-03-21 1974-10-15 Smithkline Corp Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203988A (en) * 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
US4241072A (en) * 1979-01-18 1980-12-23 Merck & Co., Inc. Substituted ureas and processes for their preparation
US4293703A (en) * 1979-01-18 1981-10-06 Merck & Co., Inc. Imidazole or imidazoline substituted ureas

Similar Documents

Publication Publication Date Title
US3852279A (en) 7-substituted -3,3a,4,5,6,7-hexahydro-3-substituted-2h- pyrazolo (4,3-c)pyridines
US4062863A (en) Pharmacologically active cyclo butenediones
KR20010075268A (en) Cyanophenyl derivatives
US3829433A (en) Substituted piperidinoalkanone oxime derivatives
CA2187214C (en) Aminostilbazole derivative and medicine
US3678169A (en) Pyridyl-2-imidazolones as anti-inflammatory agents
US3740409A (en) 2-amino(and 2-aminomethyl)-2-heterocyclic-thioacetamides
US3825547A (en) N-alkenyl and n-alkynyl thioamides
US3896233A (en) Pharmaceutical compositions and methods of inhibiting gastric acid secretion
US3337565A (en) alpha-(3-pyridyl)-beta-hydroxy-alpha-(substituted phenyl)-acrylonitrile and derivatives thereof
US3749728A (en) N-cycloalkyl and n-cycloalkane-alkylthioamides
US3898335A (en) Pharmaceutical compositions and methods of inhibiting gastric acid secretion
US3897555A (en) Pharmaceutical compositions and method of inhibiting gastric acid secretion
US3410851A (en) Derivatives of flavone
US3853865A (en) N-aminomethyl-2-amino(and 2-amino-methyl)-2-heterocyclic-thioacetamides
US3933811A (en) N-aminomethyl-2-amino(and 2-amino-methyl)-2-(2-quinolyl)-thioacetamides
US3971786A (en) Pyridyl alkylguanidine compounds, composition therewith, and methods of inhibiting H-2 histamine receptors
US4514408A (en) N-substituted nicotinamide 1-oxide as histamine H2 receptor blockers
CN101124208A (en) Novel heteroaryl acetamide
US3897420A (en) 2-Aminoalkyl-7-substituted-3,3a,4,5,6,7-hexahydro-3-substituted-2H-pyrazolo(4,3-c)pyridines
US3923809A (en) 5-Alkoxy-5-heterocyclic-1,2,3,6-tetrahydro-4(5H)-pyrimidinethiones
US3842173A (en) Pharmaceutical compositions and methods of inhibiting gastric acid secretion
US4065451A (en) 1,3-Dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts
US3882126A (en) 2-amino(and 2-aminomethyl)-2-quinolylthioacetamides
US3931162A (en) N-Aminomethyl heterocyclic thioacetamides

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BECKMAN CORPORATION

Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769

Effective date: 19820304

Owner name: SMITHKLINE BECKMAN CORPORATION, PENNSYLVANIA

Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769

Effective date: 19820304